Abstract: The present invention relates to methods and compositions for characterization of global cellular changes in response to introduction of viral vector compositions into target cells. It more particularly refers to a method for assessing the quality of a viral vector composition for a transgene transfer into target cells comprising measuring the expression level of at least one biomarker selected in the group consisting of CXCL2 and EREG and/or of at least one biomarker selected in the group consisting of ASPM, AURKB, CENPA, CENPF, CKS1B, E2F8, ERCC6L, FAM83D, KIFC1, MKI67, NEK2, NUSAP1, OIP5, PRC1, RRM2, SGOL1, SPC25, TOP2A and TTK.
Type:
Grant
Filed:
July 26, 2013
Date of Patent:
February 14, 2017
Assignee:
VECTALYS
Inventors:
Pascale Bouillé, Régis Gayon, Alexandra Iché
Abstract: Methods for the detection of, or the risk of, bladder cancer in a patient, comprising assaying for the presence of a combination of at least two biomarkers selected from CEA, VEGF, IL-8, NGAL, NSE, IL-2, EGF, TM, d-Dimer, MMP-9, IL-6, IL-4, MMP-9/NGAL, FAS, CRP, TUP and NMP22 in one or more samples isolated from a patient wherein detecting the presence of a combination of at least two biomarkers in the one or more samples indicates the presence or risk of bladder cancer.
Type:
Grant
Filed:
July 29, 2010
Date of Patent:
February 7, 2017
Assignee:
RADOX LABORATORIES LIMITED
Inventors:
Mark W. Ruddock, Cherith N. Reid, Kathleen Williamson, John V. Lamont, Stephen P. Fitzgerald
Abstract: Provided is a method for identifying human immunodeficiency virus (HIV) in a sample. The invention involves use of a plurality of fluorescently labeled oligonucleotide probes and flow cytometry to detect the presence or absence of HIV in macrophages that are obtained from a mucosal surface. The invention is particularly useful for detecting HIV infection prior to seroconversion.
Type:
Grant
Filed:
November 21, 2012
Date of Patent:
January 31, 2017
Assignees:
Cornell University, Liverpool School of Tropical Medicine
Inventors:
David G. Russell, Henry Mwandumba, Kondwani Jambo
Abstract: The present invention provides nucleic acid molecules, DNA constructs, plasmids, and methods for post-transcriptional regulation of gene expression using RNA molecules to both repress and activate translation of an open reading frame. Repression of gene expression is achieved through the presence of a regulatory nucleic acid element (the cis-repressive RNA or crRNA) within the 5? untranslated region (5? UTR) of an mRNA molecule. The nucleic acid element forms a hairpin (stem/loop) structure through complementary base pairing. The hairpin blocks access to the mRNA transcript by the ribosome, thereby preventing translation. In particular, in embodiments of the invention designed to operate in prokaryotic cells, the stem of the hairpin secondary structure sequesters the ribosome binding site (RBS). In embodiments of the invention designed to operate in eukaryotic cells, the stem of the hairpin is positioned upstream of the start codon, anywhere within the 5? UTR of an mRNA.
Type:
Grant
Filed:
November 14, 2003
Date of Patent:
January 3, 2017
Assignee:
Trustees of Boston University
Inventors:
James J. Collins, Farren J. Isaacs, Charles R. Cantor, Daniel J. Dwyer
Abstract: MicroRNAs (miRNA) are a recently discovered class of small non-coding RNAs (17-14 nucleotides). Due to their function as regulators of gene expression they play a critical role both in physiological and in pathological processes, such as cancer. The present invention provides novel methods for diagnosing a state of health based on the determination of specific miRNAs that have altered expression levels in different conditions, e.g. disease states compared to healthy controls.
Type:
Grant
Filed:
June 30, 2015
Date of Patent:
December 27, 2016
Assignee:
Comprehensive Biomarker Center GmbH
Inventors:
Andreas Keller, Eckart Meese, Anne Borries, Markus Beier
Abstract: The present invention provides methods of preventing or delaying the development of cancer (e.g., breast cancer) in BRCA1 mutation positive patients by beginning progesterone receptor antagonist treatment at an early age (e.g., by age 35, 30, or 25). In certain embodiment, such early treatment is long-term treatment, which may substitute or delay a preventative ovariectomy, single or double mastectomy (e.g., in patients wishing to delay or avoid a mastectomy, or patients that cannot afford a mastectomy).
Type:
Grant
Filed:
August 19, 2013
Date of Patent:
December 13, 2016
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: A method for determining a prognosis for survival for a patient with breast cancer is described. Also described is a method for monitoring the effectiveness of a course of treatment for a patient with breast cancer, and the use of such a method in a kit. A kit determining the level of RINF is also described.
Type:
Grant
Filed:
December 8, 2009
Date of Patent:
December 6, 2016
Assignee:
Bergen Teknologioverforing AS
Inventors:
Frederic Pendino, Johan R. Lillehaug, Thomas Aloysius, Stian Knappskog
Abstract: The present invention relates to a method for the production of a library comprising recombinant derivatives of the SH3 domain of the Fyn kinase of SEQ ID NO: 1 as well as a method for selecting from a library comprising recombinant derivatives of the SH3 domain of the Fyn kinase of SEQ ID NO: 1 one or more of said derivatives having a specific binding affinity to a protein or peptide.
Abstract: Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer.
Type:
Grant
Filed:
December 12, 2011
Date of Patent:
November 22, 2016
Assignee:
AAB Patent Holding ApS
Inventors:
Lars Dyrskjøt Andersen, Torben Falck Orntoft
Abstract: The invention provides products of manufacture for screening for compositions that can modify a cell's gene expression profile, and methods for making and using them. In one embodiment, the invention provides products of manufacture and methods comprising a high content, high throughput screening for a composition (e.g., chemicals, small molecules) that can modify a cell's physiology based on the composition's ability to modify the cell's gene expression signature.
Type:
Grant
Filed:
January 20, 2011
Date of Patent:
November 22, 2016
Assignee:
The Regents of the University of California
Abstract: An object of the present invention is to provide a method for increasing the expression of foreign genes, in particular, using a promoter, an enhancer, and the like, and an expression cassette containing a promoter, an enhancer, and the like, by which gene expression can be increased. The purpose is achieved with the use of the gene expression cassette comprising a DNA construct containing a gene to be expressed and a poly A addition sequence that are located downstream of a 1st promoter, and further comprising an enhancer or a 2nd promoter ligated downstream of the DNA construct.
Type:
Grant
Filed:
November 19, 2010
Date of Patent:
November 15, 2016
Assignees:
National University Corporation Okayama University, Momotaro-Gene Inc.
Abstract: Engineered polypeptides useful in synthesizing acyl amino acids are provided. Also provided are methods of making acyl amino acids using engineered polypeptides. In certain embodiments, an acyl amino acid produced using compositions and/or methods of the present invention comprises cocoyl glutamate.
Type:
Grant
Filed:
July 19, 2011
Date of Patent:
November 15, 2016
Assignee:
MODULAR GENETICS, INC.
Inventors:
Kevin A. Jarrell, Prashanth Vishwanath, Gabriel Reznik
Abstract: Methods and kits for selectively enriching non-random polynucleotide sequences are provided. Methods and kits for generating libraries of sequences are provided. Methods of using selectively enriched non-random polynucleotide sequences for detection of fetal aneuploidy are provided.
Abstract: In one embodiment, the disclosure provides methods and systems for identifying viral nucleic acids in a sample. In another embodiment the invention provides methods for viral genome assembly and viral discovery using small inhibitory RNAs, or “small silencing,” RNAs (siRNAS), micro-RNAs (miRNAs) and/or PIWI-interacting RNAs (piRNAs), including siRNAS, miRNAs and/or piRNAs isolated or sequenced from invertebrate organisms such as insects (Anthropoda), nematodes (Nemapoda), Mollusca, Porifera, and other invertebrates, and/or plants, fungi or algae, Cyanobacteria and the like.
Type:
Grant
Filed:
June 1, 2010
Date of Patent:
November 15, 2016
Assignee:
The Regents of the University of California
Abstract: The invention provides compositions and methods for determining the fraction of fetal nucleic acids in a maternal sample comprising a mixture of fetal and maternal nucleic acids. The fraction of fetal nucleic acids can be used in determining the presence or absence of fetal aneuploidy.
Type:
Grant
Filed:
May 1, 2012
Date of Patent:
November 15, 2016
Assignee:
VERINATA HEALTH, INC.
Inventors:
Richard P. Rava, Yue-Jen Chuu, Manjula Chinnappa, David A. Comstock, Gabrielle Heilek, Michael Hunkapiller
Abstract: Disclosed are methods for detecting, diagnosing or monitoring a renal cancer in a subject. The methods include detecting quantity of one or more polypeptides or fragments thereof comprised by body fluid such as urine, wherein the one or more polypeptides or fragments thereof, can be present at elevated levels in a subject with, a kidney cancer, as compared to a subject without a kidney cancer. Non-limiting examples of such polypeptides include aquaporin-1, adipose differentiation-related protein, and paired box protein-2. Antibody probes can be used to detect or quantify the polypeptides. In some embodiments, mass spectroscopy can be used to detect or quantify the polypeptides, or to identify a polypeptide in a body fluid sample from a subject with a kidney cancer.
Type:
Grant
Filed:
June 25, 2015
Date of Patent:
November 15, 2016
Assignee:
Washington University
Inventors:
Evan David Kharasch, Jeremiah J. Morrissey
Abstract: Methods and compositions for inhibiting Nrf1 activity are provided for enhancing apoptosis in mammalian cells. Apoptosis is enhanced in mammalian cells by co-inhibiting Nrf1 activity and proteasome activity. Methods for identifying Nrf1 inhibitors are provided using an assay for screening Nrf1 inhibitors that enhance proteasome inhibition by preventing induced proteasome expression.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
November 15, 2016
Assignees:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIFORNIA INSTITUTE OF TECHNOLOGY
Inventors:
Raymond J. Deshaies, Senthil Radhakrishnan, Candy S. Lee, Jefferson Y. Chan
Abstract: Sequences of a serotype 8 adeno-associated virus and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles.
Type:
Grant
Filed:
January 16, 2015
Date of Patent:
November 15, 2016
Assignee:
The Trustees of the University of Pennsylvania
Inventors:
Guangping Gao, James M. Wilson, Mauricio R. Alvira
Abstract: Disclosed herein are methods of detecting non-natural amino acids and polypeptides that include at least one non-natural amino acid. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of functionalities, including but not limited to oxime, carbonyl, and/or hydroxylamine groups. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, and methods for detecting such polypeptides.